LCTX icon

Lineage Cell Therapeutics
LCTX

Overview Fund Activity

107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K

Top Buyers

1
BlackRock
1
BlackRock
New York
$12.2M
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$9.15M
3
State Street
3
State Street
Massachusetts
$4.59M
4
Two Sigma Investments
4
Two Sigma Investments
New York
$366K
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.39M

Top Sellers

1
DWM
1
Destination Wealth Management
California
$0
2
Renaissance Technologies
2
Renaissance Technologies
New York
$300K
3
Deutsche Bank
3
Deutsche Bank
Germany
$517K
4
MHP
4
Manatuck Hill Partners
Connecticut
$0
5
LCM
5
Laurion Capital Management
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
PA
126
Parallel Advisors
California
$0 274 +274 New
2 3 4 5
6